Hi Southoz, great post.Picking up from your point about the...

Hi Southoz, great post.

Picking up from your point about the outcome of CAN004, the FDA has a program called "Conditional Approval", that allows for commercialisation on a limited basis after a Phase 2 trial (assuming efficacy and side effect data is acceptable). The company can then conduct the phase 3 trial whilst commecial sales are underway. It was a topic of some discussion with ML and Dr Gagorsky during the coffee session after the AGM.

I agree, there's a number of catalysts over the course of the next couple of years that should demonstrate whether Cvac and the company are moving forward in a positive manner.

How the market responds is another matter entirely. last weeks announcement of a relatively minor issue saw a significant over-reaction on the ASX. As you pointed out in a previous post, that was not replicated in the USA, presumably because they had more time to consider the ann and generally have a better understanding of bio-tech than our market does.

What we experienced here was a little P & D rally. The evidence is clear from the flurry of wildy enthusiatic posts on this forum from new posters. A bit like a flock of seagulls, they fly in, make a lot of noise, #### all over the place and then fly away. Things then return to normal until the next time a potato chip falls on the ground.